- Home
- DINO vs MDGL Comparison
DINO vs MDGL Comparison
Compare DINO & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DINO
- MDGL
- Stock Information
- Founded
- DINO 1947
- MDGL 2011
- Country
- DINO United States
- MDGL United States
- Employees
- DINO N/A
- MDGL N/A
- Industry
- DINO Oil & Gas Production
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- DINO Energy
- MDGL Health Care
- Exchange
- DINO Nasdaq
- MDGL Nasdaq
- Market Cap
- DINO 6.6B
- MDGL 6.8B
- IPO Year
- DINO N/A
- MDGL N/A
- Fundamental
- Price
- DINO $34.12
- MDGL $294.64
- Analyst Decision
- DINO Buy
- MDGL Strong Buy
- Analyst Count
- DINO 10
- MDGL 10
- Target Price
- DINO $43.78
- MDGL $420.63
- AVG Volume (30 Days)
- DINO 2.7M
- MDGL 373.7K
- Earning Date
- DINO 05-01-2025
- MDGL 05-01-2025
- Dividend Yield
- DINO 5.85%
- MDGL N/A
- EPS Growth
- DINO N/A
- MDGL N/A
- EPS
- DINO N/A
- MDGL N/A
- Revenue
- DINO $27,923,000,000.00
- MDGL $317,383,000.00
- Revenue This Year
- DINO N/A
- MDGL $230.69
- Revenue Next Year
- DINO $0.57
- MDGL $74.76
- P/E Ratio
- DINO N/A
- MDGL N/A
- Revenue Growth
- DINO N/A
- MDGL N/A
- 52 Week Low
- DINO $24.66
- MDGL $200.08
- 52 Week High
- DINO $58.73
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- DINO 67.49
- MDGL 39.29
- Support Level
- DINO $32.39
- MDGL $287.46
- Resistance Level
- DINO $33.43
- MDGL $349.00
- Average True Range (ATR)
- DINO 0.97
- MDGL 17.20
- MACD
- DINO 0.59
- MDGL -2.36
- Stochastic Oscillator
- DINO 88.11
- MDGL 11.67
About DINO HF Sinclair Corporation
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.